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Abstract
High blood pressure (BP) is the most common cardiovascular risk factor worldwide and a major contributor to heart disease
and stroke. We previously discovered a BP-associated missense SNP (single nucleotide polymorphism)–rs2272996–in the
gene encoding vanin-1, a glycosylphosphatidylinositol (GPI)-anchored membrane pantetheinase. In the present study, we
first replicated the association of rs2272996 and BP traits with a total sample size of nearly 30,000 individuals from the
Continental Origins and Genetic Epidemiology Network (COGENT) of African Americans (P = 0.01). This association was
further validated using patient plasma samples; we observed that the N131S mutation is associated with significantly lower
plasma vanin-1 protein levels. We observed that the N131S vanin-1 is subjected to rapid endoplasmic reticulum-associated
degradation (ERAD) as the underlying mechanism for its reduction. Using HEK293 cells stably expressing vanin-1 variants,
we showed that N131S vanin-1 was degraded significantly faster than wild type (WT) vanin-1. Consequently, there were only
minimal quantities of variant vanin-1 present on the plasma membrane and greatly reduced pantetheinase activity.
Application of MG-132, a proteasome inhibitor, resulted in accumulation of ubiquitinated variant protein. A further
experiment demonstrated that atenolol and diltiazem, two current drugs for treating hypertension, reduce the vanin-1
protein level. Our study provides strong biological evidence for the association of the identified SNP with BP and suggests
that vanin-1 misfolding and degradation are the underlying molecular mechanism.
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Introduction
Hypertension (HTN) or high blood pressure (BP) is common in
populations worldwide and a major risk factor for cardiovascular
disease (CVD) and all-cause mortality [1]. Although it is observed
across ethnically diverse populations, the prevalence of HTN in
the US varies from 27% in persons of European ancestry to 40%
among those of African ancestry [2]. BP is a moderately heritable
trait and affected by the combined effects of genetic and
environmental factors, with heritable factors cumulatively ac-
counting for 30–55% of the variance [3]. After age 20, African
Americans have higher BP than other US race/ethnicities [4–6]
and the progression from pre-HTN to HTN occurs one year
eariler on average [7]. Increased rates of HTN among African
Americans are the main factor contributing to their greater risk of
CVD and end-stage renal disease compared to US whites [8,9].
Given the widespread occurrence of this condition, and our as yet
limited ability to reduce the disease burden, identifying the genetic
variants of BP phenotypes could elucidate the underlying biology
of high BP and reduce the CVD prevalence.
Identification of genetic variants of consequence for HTN
remains a significant challenge, owing in large part to the complex
and polygenic nature of the disorder and the imprecision with
which the phenotype is measured [10]. Using admixture mapping
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analysis of data from the Family Blood Pressure Program, we
recently identified a genomic region on chromosome 6 harboring
HTN-associated variants [11]. The same region on chromosome 6
was replicated in an admixture mapping analysis based on the
African Americans enrolled in the Dallas Heart Study [12]. By
further genotyping the functional variants in the region of interest
on chromosome 6, the VNN1 gene, in particular SNP rs2272996
(N131S) was found to account for the association with BP in both
African Americans and Mexican Americans, but this association
was not observed in European Americans [12]. Fava et al. [13]
recently argued that rs2294757 (T26I), rather than N131S, was a
more likely functional variant accounting for the effect on BP
because it is located in a splicing regulation site in VNN1, but
these investigators only found a weak association between T26I
and both DBP and HTN in one of the two studies that they
carried out. The results of this study are consistent with the lack of
evidence for association observed in European Americans in the
Dallas Heart Study [12].
VNN1 encodes the protein vanin-1, a glycosylphosphatidylino-
sitol (GPI)-anchored membrane protein [14,15]. Vanin-1 is widely
expressed in a variety of tissues, with higher expression in liver,
kidney and blood [16]. Vanin-1 is a pantetheinase, a member of
the biotinidase branch of the nitrilase superfamily [17]. Vanin-1
hydrolyzes pantetheine to pantothenic acid (vitamin B5) and
cysteamine, a potent regulator of oxidative stress. In vanin-1 null
mice free cysteamine is undetectable, indicating vanin-1’s indis-
pensable role in generating cysteamine under physiological
conditions [18]. Therefore, vanin-1 plays an essential role in
regulating oxidative stress via cysteamine generation. A linkage
between oxidative stress and HTN has been hypothesized for
many years [19–21]. Furthermore, vanin-1 was reported to be
involved in cardiovascular diseases [22,23]. Overexpression of
vanin-1 was associated with progression to chronic pediatric
immune thrombocytopenia (ITP) [24], and was shown to lead to
hyperglycemia [25]. Vanin-12/2 mice showed protective effects
against a variety of phenotypes, such as oxidative stress [26],
intestinal inflammation [27], and colon cancer [28], mostly due to
higher glutathione storage to maintain a more reducing environ-
ment. As a consequence, vanin-1’s pantetheinase activity may offer
a physiologic rationale for BP regulation with loss of vanin-1
function.
In this study, we first investigated the association evidence of the
missense variant rs2272996 (N131S) in VNN1 and BP phenotypes
by performing a meta-analysis of nearly 30,000 African ancestry
subjects from 19 independent cohorts from the Continental
Origins and Genetic Epidemiology Network (COGENT). We
next examined whether there were other variants in VNN1
associated with BP traits. Lastly, we conducted molecular
experiments to establish a functional connection between N131S
vanin-1 and HTN.
Results
Meta-analysis of VNN1 with BP
The study samples were the African-ancestry subjects from the
COGENT, which includes 19 discovery cohorts. The details are
described elsewhere by Franceschini et al [29]. Briefly, the
phenotype-genotype association analysis was performed in each
cohort separately. Systolic BP (SBP) and diastolic BP (DBP) were
treated as continuous variables. For individuals reporting the use
of antihypertensive medications, BP was adjusted by adding 10
and 5 mmHg to SBP and DBP respectively [30]. SBP and DBP
were adjusted for age, age2, body mass index (BMI) and gender in
linear regression models. The results of association between SNP
rs2272996 and SBP or DBP for the 18 cohorts are presented in
Figure 1. This SNP was not available in the GeneSTAR cohort.
The corresponding allele frequencies in the different studies are
listed in Supplementary Table S1. Among the 18 cohorts, 12 and
10 have positive effect sizes for SBP (P = 0.048) and DBP
(P = 0.24), respectively, comparing to 9 expected under null
hypothesis of no association between this SNP and BP. We next
performed meta-analysis by applying both fixed-effect [31,32] and
random-effect [33] models to estimate the overall effect. SNP
rs2272996 was significantly associated with SBP in both fixed-
effect (P = 0.01) and random-effect (P = 0.04) models (Table 1).
However, we did not observe evidence of genotype-phenotype
association for DBP.
Among the individual cohort analyses, the Maywood cohort
had a sample size of 743 and was the only cohort that showed
significant association with rs2272996 for both SBP (P = 0.016)
and DBP (P = 0.0003), however the direction of the association
was opposite to what was found in the test for overall effects
(Figure 1). The distributions of SBP, DBP, age and BMI did not
suggest that the Maywood was an outlier in epidemiologic
characteristics (Supplementary Figure S1), with the exception
that the sampling strategy for this cohort was based on exclusion of
persons on antihypertensive medications (antihypertensive medi-
cation rate was 0.7%). The Nigeria cohort also included a low
antihypertensive medication rate but this was a result of
inaccessibility to medications (Supplementary Figure S2). When
analyses were repeated after exclusion of the Maywood cohort, the
association of BP and rs2272996 was substantially improved
(P = 0.003 for SBP, Table 1). The different association evidence
between Maywood and other cohorts may suggest genetic
heterogeneity or possible interaction between gene and environ-
ment factors, although further studies are needed to address this
possibility.
Searching for additional BP variants in VNN1
Since additional genetic variants in VNN1 might be associated
with BP, we examined available known variants in VNN1
including 10 kb up- and down-stream of the gene. A total of
Author Summary
Hypertension (HTN) or high blood pressure (BP) is
common worldwide and a major risk factor for cardiovas-
cular disease and all-cause mortality. Identification of
genetic variants of consequence for HTN serves as the
molecular basis for its treatment. Using admixture map-
ping analysis of the Family Blood Pressure Program data,
we recently identified that the VNN1 gene (encoding the
protein vanin-1), in particular SNP rs2272996 (N131S), was
associated with BP in both African Americans and Mexican
Americans. Vanin-1 was reported to act as an oxidative
stress sensor using its pantetheinase enzyme activity.
Because a linkage between oxidative stress and HTN has
been hypothesized for many years, vanin-1’s pantethei-
nase activity offers a physiologic rationale for BP regula-
tion. Here, we first replicated the association of rs2272996
with BP in the Continental Origins and Genetic Epidemi-
ology Network (COGENT), which included nearly 30,000
African Americans. We further demonstrated that the
N131S mutation in vanin-1 leads to its rapid degradation in
cells, resulting in loss of function on the plasma
membrane. The loss of function of vanin-1 is associated
with reduced BP. Therefore, our results indicate that vanin-
1 is a new candidate to be manipulated to ameliorate HTN.
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105 other SNPs were available in the 19 cohorts. SNP rs7739368
had the smallest p values for association with SBP using either
fixed-effect model (P = 0.004) or random-effect model (P = 0.004,
Supplementary Table S2), but this was not significant after
correcting for multiple comparisons. This SNP is ,7 k bp’s
upstream of VNN1 adjacent to the PU.1 transcription factor
binding region (306 bp’s upstream).
The vanin-1 expression in human plasma samples is
closely linked with both genotypic N131S mutation and
phenotypic HTN
To understand the function of N131S vanin-1 in relation to
HTN, plasma samples from Nigeria HTN patients and normo-
tensives with WT (TT) or homozygous N131S (CC) vanin-1 were
collected (6 samples per group, 4 groups). The same amount of
total plasma protein from each sample was subjected to Western
blot analysis: a clean vanin-1 protein band appeared at 70 kD
(Figure 2A), consistent with previous reports [14,34]. The plasma
vanin-1 protein in homozygous N131S vanin-1 was significantly
lower than that in WT vanin-1 in both hypertensive and
normotensive groups (P = 1.6461025 and 0.014, Figure 2A, see
Figure 2B for quantification), indicating that the N131S muta-
tion is a functional variant that is associated with substantially less
steady-state vanin-1 protein. Furthermore, the plasma vanin-1
protein in normotensive groups with WT vanin-1 (samples 13–18)
was significantly lower than that in HTN patients with WT vanin-
1 (samples 1–6) (P = 0.042) (Figure 2A, see Figure 2B for
quantification). These results demonstrated that vanin-1 expres-
sion is associated with both the genotypic N131S mutation and
phenotypic HTN, with the former exerting stronger effect. Lastly,
the plasma vanin-1 protein in normotensive groups with homo-
zygous N131S vanin-1 (samples 19–24) is also lower than that in
HTN patients with homozygous N131S vanin-1 (samples 7–12)
although it was not statistically significant (P = 0.13), probably due
to the already exceedingly low vanin-1 quantity. These results
suggest that the WT vanin-1 is associated with increased plasma
vanin-1 protein expression, and increased HTN risk.
N131S mutation leads to significantly lower total and
surface vainin-1 protein level and fractional
pantetheinase activity compared to WT and T26I vanin-1
variants
We tested two variants, N131S and T26I, as regards how they
influence the total vanin-1 protein levels because other investiga-
tors have suggested that T26I may be a candidate variant for BP
variation as well [13]. We utilized the human embryonic kidney
293 (HEK293) cells stably expressing these vanin-1 variants
because HEK293 cells have high transfection efficiency and
physiologically-relevant cell environment for vanin-1 protein
expression [23]. Significantly lower total vanin-1 proteins were
Figure 1. Association of SNP rs2272996 with SBP (A) and DBP (B) for each cohort. The effect size (Beta) and 95% confidence interval are
presented in terms of the reference allele T. Overall: all COGENT cohorts are included in the meta-analysis. Overall 2: Maywood cohort is excluded
from the meta-analysis. Biological Bank of Vanderbilt University (BioVU); Atherosclerosis Risk In Communities (ARIC); Coronary Artery Risk
Development in Young Adults (CARDIA); Cleveland Family Study (CFS); Jackson Heart Study (JHS); Multi-Ethnic Study of Atherosclerosis (MESA);
Cardiovascular Health Study (CHS); Genetic Study of Atherosclerosis Risk (GeneSTAR); Genetic Epidemiology Network of Arteriopathy (GENOA); The
Healthy Aging in Neighborhoods of Diversity Across the Life Span Study (HANDLS); Health, Aging, and Body Composition (Health ABC) Study; The
Hypertension Genetic Epidemiology Network (HyperGEN); Mount Sinai, New York City, USA Study (Mt Sinai Study); Women’s Health Initiative SNP
Health Association Resource (WHI); Howard University Family Study (HUFS); Bogalusa Heart Study (Bogalusa); Sea Islands Genetic Network (SIGNET);
Loyola Maywood Study (Maywood); and Loyola Nigeria Study (Nigeria).
doi:10.1371/journal.pgen.1004641.g001
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detected in the cells expressing N131S vanin-1, whereas similar
vanin-1 protein levels were detected in cells expressing T26I
vanin-1 compared to cells expressing WT vanin-1 (Figure 3A,
quantification shown below).
Because vanin-1 is a GPI-anchored membrane protein, it needs
to traffic efficiently to the plasma membrane for its pantetheinase
activity. We hypothesized that N131S substantially reduces the
trafficking of vanin-1 protein to the plasma membrane, whereas
T26I does not. Using a surface biotinylation assay [35] , we
observed that the N131S mutation led to significantly lower
plasma membrane expression, whereas in cells expressing the
T26I mutation, vanin-1 surface expression was similar to that
observed in WT cells (Figure 3B, quantification shown below).
We further confirmed that the variation in vanin-1 protein
expression resulted in corresponding functional consequences for
N131S and T26I mutations. A cell-based fluorescence assay was
carried out to record the kinetics of pantetheinase activity by
vanin-1 variants [36]. The cells expressing T26I vanin-1 had
similar pantetheinase activity compared to cells expressing WT
vanin-1; however, cells expressing N131S vanin-1 retained
approximately 9% of the pantetheinase activity, by quantifying
the fluorescence signals at the kinetic steady state at 57 minutes
(Figure 3C). These data taken together provide evidence of less
protein, less membrane trafficking, and lower enzymatic activity of
the N131S protein as compared to both the wild type and the
T26I variant.
N131S vanin-1 is subjected to rapid endoplasmic
reticulum-associated degradation (ERAD)
To determine the mechanism of loss of surface N131S vanin-1,
we sought to confirm that N131S vanin-1 is rapidly degraded. A
cycloheximide (CHX) chase assay was used to quantify the half-life
of vanin-1 variants in HEK293 cells: WT vanin-1 had a half-life of
240 min; T26I vanin-1, 232 min; N131S vanin-1, 76 min,
respectively (Figure 4A, quantification in Figure 4B). Thus,
N131S vanin-1 has a much faster degradation rate than WT
vanin-1, whereas T26I vanin-1 is degraded at a rate similar to that
of WT vanin-1.
To confirm that misfolded N131S vanin-1 is subjected to
ERAD, we applied MG-132 to the cells, which is a potent
proteasome inhibitor. MG-132 treatment resulted in the accu-
mulation of ubiquitinated proteins and substantially more total
vanin-1 proteins (Figure 4C, cf. lane 2 to lane 1), indicating that
efficient proteasome inhibition prevents the degradation of
N131S vanin-1. Furthermore, using immunoprecipitation against
vanin-1, we confirmed that MG-132 treatment resulted in
ubiquitination of N131S vanin-1 (Figure 4C, cf. lane 5 to lane
4). These data indicate that N131S vanin-1 is subjected to rapid
ERAD, resulting in loss of functional vanin-1 on the plasma
membrane.
We hypothesize that rapid degradation of N131S vanin-1
resulted from its misfolding in the endoplasmic reticulum (ER).
The endoglycosidase H (endo H) enzyme selectively cleaves
vanin-1 after asparaginyl-N-acetyl-D-glucosamine (GlcNAc) in
the N-linked glycans incorporated in the ER. After the high-
mannose form is enzymatically remodeled in the Golgi, endo H is
unable to remove the oligosaccharide chain. Therefore, endo H-
resistant vanin-1 bands (with higher molecular weight) represent
properly folded, post-ER vanin-1 glycoforms, which traffic at
least to the Golgi compartment. The N131S mutation resulted in
much less intense endo H-resistant bands than WT vanin-1
(Figure 4D, cf. lane 6 to lane 2), whereas T26I did not
(Figure 4D, cf. lane 4 to lane 2). The ratio of endo H-resistant to
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The trafficking efficiency of N131S vanin-1 was less than WT
vanin-1, indicating that N131S vanin-1 does not fold properly in
the ER. These data support the conclusion that N131S vanin-1 is
misfolded in the ER and subsequently degraded by the ERAD
pathway.
HTN drugs decrease endogenous vanin-1 protein level
To determine whether vanin-1 is a target of current anti-
hypertensive drugs, we tested the effect of two commonly
prescribed HTN drugs with different known drug mechanisms
on endogenous vanin-1 protein level. Human monocyte THP-1
cells were used because they were derived from human blood and
have high endogenous WT vanin-1 protein expression levels.
Two HTN drugs used are diltiazem [37], an L-type calcium
channel blocker, and atenolol, a selective b1 adrenergic receptor
blocker [38]. Treatment of THP-1 cells with diltiazem (10 mM) or
atenolol (10 mM) for 1d or 3d decreased the endogenous total
vanin-1 protein significantly in a time-dependent manner
(Figure 5A, quantification shown below). Furthermore, applica-
tion of diltiazem for 3d decreased the endogenous total vanin-1
protein significantly in a dose-dependent manner (Figure 5B,
quantification shown below). This indicates that vanin-1 is a
molecular target of current HTN drugs, which was previously
unknown and confirms the relevance of vanin-1 to the regulation
of blood pressure. Therefore, exploring other compounds that
decrease vanin-1 level may lead to discovery of novel antihyper-
tensive drugs, especially those with previously unknown function
in HTN.
Figure 2. The vanin-1 expression in human plasma samples is closely linked with both genotypic N131S mutation and phenotypic
HTN. Human plasma samples were collected from 6 HTN patients with WT VNN1 (samples 1 to 6), 6 HTN patients with homozygous N131S VNN1
(samples 7 to 12), 6 healthy controls with WT VNN1 (samples 13 to 18), and 6 healthy controls with homozygous N131S VNN1 (samples 19 to 24).
Same amount of total plasma proteins were subjected to 8% SDS-PAGE and Western blot analysis; transferrin serves as loading control. (A). IB:
immunoblotting. WT: wild type. The vanin-1 protein band intensity was quantified using ImageJ software from the NIH, shown in (B). NS: not
significant. Data are reported as mean 6 SEM.
doi:10.1371/journal.pgen.1004641.g002
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Figure 3. N131S mutation leads to significantly lower total and surface vainin-1 protein and fractional pantetheinase activity
compared to WT, whereas T26I does not. HEK293 cells stably expressing WT, T26I or N131S vanin-1 were generated using the G418 selection
method. HEK293 cells transfected with empty vector (EV) were used as a negative control. (A) Cells were lysed and 30 mg of total protein were
subjected to 8% SDS-PAGE and Western blot analysis using a rabbit polyclonal anti-vanin-1 antibody (Pierce antibodies) (n = 3). b-actin serves as a
loading control. (B) Cells were incubated with the membrane-impermeable biotinylation reagent Sulfo-NHS SS-Biotin (Pierce) and biotinylated
surface proteins were affinity-purified using immobilized neutravidin-conjugated agarose beads (Pierce). Surface proteins were subjected to 8% SDS-
PAGE and Western blot analysis using a rabbit polyclonal anti-vanin-1 antibody (Pierce antibodies) (n = 3). The protein band intensity in (A) and (B)
was quantified using ImageJ software from the NIH. Data is reported as mean 6 SEM. ** p,0.01. NS: non-significant. (C) A cell-based fluorescence
assay was used to evaluate vanin-1 variants’ pantetheinase activity according to published procedure with modifications [36]. The substrate,
pantothenate-7-amino-4-methylcoumarin (Pantothenate-AMC) was chemically synthesized. Cells were lysed and 10 mg of total proteins were added
to the substrate Pantothenate-AMC (5 mM) in a 100 mL final volume. Fluorescence signals at excitation 350 nm and emission 460 nm measuring the
released AMC were recorded every 3 min using a fluorescence plate reader. A 60-min kinetics assay in four replicates and three biological replicates
was carried out. Buffer only and HEK293 cells transfected with empty vector (EV) were used as negative controls for non-specific pantetheinase
activity.
doi:10.1371/journal.pgen.1004641.g003
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Discussion
A major methodological issue that has greatly increased the
challenges faced in the genetic epidemiology of BP is the high
noise-to-signal ratio in the phenotype. This problem has
numerous causes, including variation in measurement proto-
cols of SBP and DBP across studies, the dynamic nature of BP
levels, and concurrent use of antihypertensive medications. In
addition, as with all polygenic disorders, the effect size for any
single gene variant is very small and a large number of genes/
variants are involved [10]. Recent large-scale BP genome-wide
association studies (GWAS) of European, Asian and African
ancestry populations demonstrated that the identified genetic
variants together explain only 1–2% of BP variation
[29,39,40]. It is thus not surprising that a large sample size is
often necessary to detect genome-wide significant effects.
An analysis method complementary to GWAS is admixture
mapping, which has been successfully applied to detect BP loci
[11,12,41]. Our group reported that the missense variant
rs2272996 (N131S) in VNN1 was associated with BP through
admixture mapping, and we conducted a follow-up association
analysis in African and Mexican American samples [11,12]. The
association evidence in European-ancestry population is however
less convincing [12,13] In the current study, we performed meta-
analysis using the COGENT consortium consisting of 19 studies
with a total sample size of nearly 30,000 African ancestry subjects
and confirmed the association evidence between rs2272996 and
SBP (P = 0.01, Table 1).
However, statistical evidence alone cannot explain the role of a
given variant on disease risk and drug response. Therefore, in our
study we decided to analyze the functional effects of the N131S
variant. Vanin-1 is a pantetheinase generating cysteamine, which
Figure 4. N131S Vanin-1 is subjected to rapid ERAD. HEK293 cells stably expressing WT, T26I or N131S vanin-1 were generated using the G418
selection method. (A) Cells were treated with cycloheximide (CHX, 100 mg/ml) for the indicated hours before being lysed. 30 mg of total protein were
subjected to 8% SDS-PAGE and Western blot analysis using a rabbit polyclonal anti-vanin-1 antibody (Pierce antibodies) (n = 3). b-actin serves as a
loading control. The protein band intensity was quantified using ImageJ software from the NIH, shown in (B). Data is reported as mean 6 SEM. (C)
Cells expressing N131S vanin-1 were treated with MG-132 (5 mM, 24 h), a potent proteasome inhibitor, before being lysed. Cell lysates were
immunoprecipitated using an anti-vanin-1 antibody and subjected to Western blot analysis. IgG was used a negative control for nonspecific binding
during immunoprecipitation (lane 3). IP: immunoprecipitation. Ub: ubiquitin. (D) Cell lysates were digested with endoglycosidase H (endoH) enzyme
before Western blot analysis. Peptide-N-glycosidase F (PNGase F) cleaves the protein at a location between the innermost GlcNAc and asparagine
residues from N-linked glycoproteins, serving as a control for unglycosylated vanin-1. EndoH resistant vanin-1 proteins fold properly in the ER and
traffic at least through the Golgi. EndoH sensitive vanin-1 proteins are immature ER vanin-1 glycoform.
doi:10.1371/journal.pgen.1004641.g004
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regulates the glutathione-dependent oxidative stress response. We
showed that the HTN-associated N131S mutation in vanin-1
significantly reduces vanin-1 total and cell surface expression.
Consequently, the N131S vanin-1 only has fractional pantethei-
nase activity on the plasma membrane, which is associated with
decreased HTN risk. Our result is consistent with the recognized
link between impaired reduction-oxidation status and the devel-
opment of HTN [19–21], and the observed protective effects in
vanin-12/2 mice in a variety of diseases, including oxidative stress
[26], intestinal inflammation [27], and colon cancer [28], mostly
due to higher glutathione storage to maintain a more reducing
environment.
We further tested the drug effects of atenolol and diltiazem in
human monocyte THP-1 cells, which have high endogenous WT
vanin-1 protein expression level. Atenolol is a selective b1
adrenergic receptor blocker and developed as a replacement for
propranolol in treating hypertension; diltiazem is a nondihydro-
pyridine member of calcium channel blockers used in treatment of
hypertension. We found that both drugs reduce the vanin-1
protein level in the THP-1 cells. The anti-hypertensive drugs may
have different and complex mechanisms leading to reduced BP,
but whether vanin-1 is targeted was previously unknown. Our
experiments filled this gap and showed vanin-1 is involved in the
BP regulation pathway. Therefore, other potent vanin-1 inhibitors
may prove to have BP reducing effects, which is especially useful
given that these inhibitors have not been studied in HTN and thus
may provide new therapeutics for HTN.
Our study presented the first functional studies of vanin-1 in
HTN association, and provides compelling evidence for the
essential role of its N131S mutation. Nonetheless, it has been
demonstrated that multiple variants in a gene may contribute to a
phenotypic variation [42,43], and it is possible that other closely
linked variants may have similar or analogous effects, or act in
combination with N131S to regulate the vanin-1 protein
expression and function. Current GWAS of HTN related traits
mainly focus on testing common variants (MAF: minor allele
frequency $5%) through pre-built chips and imputations based on
HapMap [44] data; to date those findings in general have modest
effect sizes [39]. Other functional and rare variants may be
identified by deep sequencing, in combination with publicly
available databases, such as the 1000 Genome Projects [45] and
the Encyclopedia of DNA Elements (ENCODE) [46]. Identifica-
tion of additional functional SNPs in VNN1 and their association
with BP should provide further evidence for vanin-1 function in
the regulation of BP.
Cell lines were used to determine that ERAD is the underlying
mechanism for vanin-1’s loss of function due to the N131S
mutation. Cell lines are commonly used for the study of molecular
mechanisms because they typically provide efficient transfection
and a physiologically-relevant cell environment for the target
protein. However, BP has a complex etiology with the involvement
of a variety of organs, such as heart, brain and kidney, which
cannot be recapitulated solely in cell lines. Although knowledge
gained from our cell system provides essential cellular mechanistic
Figure 5. HTN drugs decrease endogenous vanin-1 protein level. Human blood-derived monocyte THP-1 cells were treated with diltiazem
(10 mM), or atenolol (10 mM) for the indicated time (A) or treated with diltiazem for 3d using the indicated concentrations (B) before being lysed for
SDS-PAGE and Western blot analysis using a rabbit polyclonal anti-vanin-1 antibody (n = 3). b-actin serves as a loading control. The protein band
intensity was quantified using ImageJ software from the NIH, shown at the bottom. Data are reported as mean 6 SEM. * p,0.05.
doi:10.1371/journal.pgen.1004641.g005
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insights into the regulation of vanin-1 and its function, the study of
BP regulation by vanin-1 calls for studies in animal models. A
hypertensive mouse or rat model, vanin-1 knockout mouse or rat
model, and N131S vanin-1 knockin mouse or rat model would be
of great interest to study the effects of vanin-1 and its mutation in
the complex physiological and metabolic systems.
Vanin-1 provides a potential candidate to be manipulated to
ameliorate HTN. Vanin-1 is a pantetheinase that contains the
conserved catalytic triad residue–glutamate, lysine and cysteine–
within the nitrilase family [47]. Based on the sequence alignment
of vanin-1 with other nitrilase family members, the conserved
catalytic triad of vanin-1 is composed of glutamate 79, lysine 178
and cysteine 211 [23]. A three-dimensional atomic model of
vanin-1 was built using the I-TASSER server (Figure S3) [48].
Neither T26 nor N131 is in the vicinity of the catalytic sites of
vanin-1. Therefore, the T26I and N131S mutations per se are not
expected to change the vanin-1 enzyme activity significantly.
Indeed, we showed that the T26I mutation did not influence
vanin-1 maturation or enzymatic activity. The N131S mutation
has much weaker pantetheinase activity, presumably due to
exceedingly low concentration of N131S vanin-1 on the plasma
membrane; however, the activity is still evident, implying that the
catalytic triad is not disrupted by this mutation.
Loss of function of vanin-1 is caused by misfolding and rapid
degradation of vanin-1 due to a single missense mutation from Asn
to Ser at position 131. As a GPI-anchored protein, to function
properly, vanin-1 needs to be trafficked efficiently to the plasma
membrane, where it acts as a pantetheinase. In accordance with
the maturation of general GPI-anchored proteins [15], vanin-1 is
co-translationally translocated into the ER for folding. Because
human vanin-1 has six potential N-linked glycosylation sites, its
maturation is presumably dictated by glycoprotein processing
machinery in the ER [49,50]. Properly folded vanin-1 is trafficked
out of the ER, through the Golgi and to the plasma membrane in
a fully functional state. Misfolded vanin-1 is recognized by the ER
quality control machinery and subjected to ERAD, being retro-
translocated to the cytosol, ubiquitinated and degraded by the
proteasome [51–54]. Cells need to maintain a delicate balance
between protein synthesis, folding, trafficking, aggregation and
degradation for individual proteins that make up the proteome in
normal physiology. This balance is dictated by the cellular protein
homeostasis (proteostasis) network, composed of a variety of sub-
networks, including the chaperone, degradation and trafficking
networks, and cellular signaling pathways that regulate proteostasis
as the core layers [55–57]. Therefore, further elucidation of the
proteostasis network for vanin-1 should provide a valuable fine-
tuning control of vanin-1 expression, function and BP.
Materials and Methods
Sample cohorts
19 cohort studies contributed to the meta-analysis of BP and
genetic variants in VNN1 in African-Americans as detailed in
Franceschini et al [29], including Biological Bank of Vanderbilt
University (BioVU); Atherosclerosis Risk In Communities (ARIC);
Coronary Artery Risk Development in Young Adults (CARDIA);
Cleveland Family Study (CFS); Jackson Heart Study (JHS); Multi-
Ethnic Study of Atherosclerosis (MESA); Cardiovascular Health
Study (CHS); Genetic Study of Atherosclerosis Risk (GeneSTAR);
Genetic Epidemiology Network of Arteriopathy (GENOA); The
Healthy Aging in Neighborhoods of Diversity Across the Life Span
Study (HANDLS); Health, Aging, and Body Composition (Health
ABC) Study; The Hypertension Genetic Epidemiology Network
(HyperGEN); Mount Sinai, New York City, USA Study (Mt Sinai
Study); Women’s Health Initiative SNP Health Association
Resource (WHI); Howard University Family Study (HUFS);
Bogalusa Heart Study (Bogalusa); Sea Islands Genetic Network
(SIGNET); Loyola Maywood Study (Maywood); and Loyola
Nigeria Study (Nigeria). Each study received IRB approval of its
consent procedures, examination and surveillance components,
data security measures, and DNA collection and its use for genetic
research.
The vanin-1 expression in human plasma samples
We selected 24 plasma samples from the International
Collaborative Study on Hypertension in Blacks (ICSHIB), in
which the study participants were recruited from Igbo-Ora and
Ibadan in southwest Nigeria as part of a long-term study on the
environmental and genetic factors underlying hypertension [58].
The ICSHIB included 1,188 subjects who were genotyped using
Affymetrix platform 6.0 chip [59]. We selected 6 subjects per
group from the high and lower SBP traits in each of TT and CC
genotype groups of SNP rs2272996. For each of these 24 subjects,
western blot analysis was performed by controlling the same
amount of total plasma protein.
Statistical analysis
The detailed statistical analysis of each cohort can be found in
Franceschini et al [29]. In brief, each study cohort received a
uniform statistical analysis protocol and analyses were conducted
accordingly. BP was measured in mmHg. For individuals
reporting use of antihypertensive medications, BP was imputed
by adding 10 and 5 mmHg for SBP and DBP, respectively. For
unrelated individuals, SNP associations for SBP or DBP were
assessed by linear regression assuming an additive model, adjusting
for age, age2, body mass index (BMI) and gender. Population
stratification was controlled by adjusting for the first 10 principal
components obtained from selected ancestry informative markers
[60,61]. For family data, association was tested using a linear
mixed effect model, where random effects account for family
structure [62].
Meta-analysis across the 19 cohorts was performed by applying
both fixed-effect [31,32] and random-effect [33] models to
estimate the overall effect. The fixed-effect model assumes that
the effect size is the same for all the included studies; the only
source of error is the random error within studies, which depends
primarily on the sample size for each study. Because the inverse
variance is roughly proportional to sample size, the fixed-effect
model provides a weighted average of the effect sizes, with the
weights being the estimated inverse of the variance of the estimate
in each study. The random-effect model assumes that the effect
sizes from studies are similar but not identical, dependent on each
study protocol; the source of error includes within-study and
among-study error [33]. It is more conservative and thus provides
relatively wider 95% confidence intervals when heterogeneity
across studies exists.
All experimental data are presented as mean 6 SEM, and any
statistical significance was calculated using two-tailed Student’s t-
test.
Reagents
MG-132, diltiazem, and atenolol were obtained from Sigma-
Aldrich. The pCMV6 plasmids containing human vanin-1 and
pCMV6 Entry Vector plasmid (pCMV6-EV) were obtained from
Origene. The human vanin-1 missense mutations, N131S and
T26I, were constructed using QuickChange II site-directed
mutagenesis Kit (Agilent Genomics), and the cDNA sequences
were confirmed by DNA sequencing, showing the single-site
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mutation of these variants. The rabbit polyclonal anti-vanin-1
antibody came from Pierce antibodies, the mouse monoclonal
anti-transferrin antibody from Santa Cruz Biotechnology, the
mouse monoclonal anti-b-actin antibody from Sigma, and the
rabbit polyclonal anti-ubiquitin antibody from Cell Signaling.
Cell culture and transfection
Human embryonic kidney 293 (HEK293) cells and human
monocytic THP-1 cells came from ATCC. THP-1 cells were
maintained in RPMI-1640 medium (Hyclone) with 10% heat-
inactivated fetal bovine serum (Sigma-Aldrich) and 1% Pen-Strep
(Hyclone) at 37uC in 5% CO2. HEK293 cells were maintained in
Dulbecco’s Modified Eagle Medium (DMEM) (Hyclone) with 10%
heat-inactivated fetal bovine serum (Sigma-Aldrich) and 1% Pen-
Strep (Hyclone) at 37uC in 5% CO2. Monolayers were passaged
upon reaching confluency with TrypLE Express (Life Technolo-
gies). HEK293 cells were grown in 6-well plates or 10-cm dishes
and allowed to reach ,70% confluency before transient transfec-
tion using Lipofectamine 2000 (Life Technologies) according to
the manufacturer’s instruction. Stable cell lines expressing vanin-1
variants (WT, N131S or T26I) were generated using the G-418
selection method. Briefly, transfected cells were maintained in
DMEM supplemented with 0.8 mg/mL G418 (Enzo Life Scienc-
es) for 15 days. G-418 resistant cells were selected for follow-up
experiments.
Western blot analysis
Cells were harvested and then lysed with lysis buffer (50 mM
Tris, pH 7.5, 150 mM NaCl, and 1% Triton X-100) supplement-
ed with Roche complete protease inhibitor cocktail. Lysates were
cleared by centrifugation (15,0006 g, 10 min, 4uC). Protein
concentration was determined by MicroBCA assay (Pierce).
Endoglycosidase H (endo H) or Peptide-N-Glycosidase F (PNGase
F) (New England Biolabs) enzyme digestion was performed
according to published procedure [35]. Aliquots of cell lysates or
human plasma samples were separated in an 8% SDS-PAGE gel,
and Western blot analysis was performed using the appropriate
antibodies. Band intensity was quantified using Image J software
from the NIH.
Biotinylation of cell surface proteins
HEK293 cells stably expressing vanin-1 variants were plated in
10-cm dishes for surface biotinylation experiments according to
published procedure [35]. Intact cells were washed twice with ice-
cold PBS and incubated with the membrane-impermeable
biotinylation reagent Sulfo-NHS SS-Biotin (0.5 mg/mL; Pierce)
in PBS containing 0.1 mM CaCl2 and 1 mM MgCl2 (PBS+CM)
for 30 min at 4uC to label surface membrane proteins. To quench
the reaction, cells were incubated with 10 mM glycine in ice-cold
PBS+CM twice for 5 min at 4uC. Sulfhydryl groups were blocked
by incubating the cells with 5 nM N-ethylmaleimide (NEM) in
PBS for 15 min at room temperature. Cells were solubilized for
1 h at 4uC in lysis buffer (Triton X-100, 1%; Tris–HCl, 50 mM;
NaCl, 150 mM; and EDTA, 5 mM; pH 7.5) supplemented with
Roche complete protease inhibitor cocktail and 5 mM NEM. The
lysates were cleared by centrifugation (16,0006g, 10 min at 4uC)
to pellet cellular debris. The supernatant contained the biotiny-
lated surface proteins. The concentration of the supernatant was
measured using microBCA assay (Pierce). Biotinylated surface
proteins were affinity-purified from the above supernatant by
incubating for 1 h at 4uC with 100 mL of immobilized neutravidin-
conjugated agarose bead slurry (Pierce). The samples were then
subjected to centrifugation (16,0006g, 10 min, at 4uC). The beads
were washed six times with buffer (Triton X-100, 0.5%; Tris–HCl,
50 mM; NaCl, 150 mM; and EDTA, 5 mM; pH 7.5). Surface
proteins were eluted from beads by boiling for 5 min with 60 mL of
LSB/Urea buffer (26Laemmli sample buffer (LSB) with 100 mM
DTT and 6 M urea; pH 6.8) for SDS-PAGE and Western blotting
analysis.
Cell-based fluorescence assay to evaluate vanin-1
variants’ pantetheinase activity
The cell-based fluorescence assay to evaluate vanin-1’s
pantetheinase activity was performed according to published
procedure with modifications [36]. The substrate, pantothenate-7-
amino-4-methylcoumarin (pantothenate-AMC) was chemically
synthesized according to published method [36]. As a pantethei-
nase, vanin-1 catalyzed the release of AMC, giving a fluorescence
signal at excitation 350 nm and emission 460 nm. HEK293 cells
expressing vanin-1 variants were lysed with lysis buffer (50 mM
Tris, pH 7.5, 150 mM NaCl, and 1% Triton X-100) supplement-
ed with Roche complete protease inhibitor cocktail. Enzyme
activity was performed using 10 mg of total proteins containing the
substrate pantothenate-AMC (5 mM), 0.5 mM DTT, 5% DMSO
in a 100 mL final volume in PBS, pH 7.5. Fluorescence signals at
excitation 350 nm and emission 460 nm measuring the released
AMC were recorded every 3 min at 37uC in 96-well plates
(Greiner Bio-One) using a fluorescence plate reader. A 60-min
kinetic assay in four replicates and three biological replicates was
carried out. Buffer only and HEK293 cells transfected with empty
vector (EV) were used as negative controls for non-specific
pantetheinase activity.
Cycloheximide (CHX) chase assay
HEK293 cells stably expressing vanin-1 variants were seeded at
2.56105 cells per well in 6-well plates and incubated at 37uC
overnight. To stop protein translation, cells were treated with
100 mg/mL cycloheximide (Ameresco) and chased for the
indicated time. Cells were then lysed for SDS-PAGE and Western
blot analysis.
Immunoprecipitation
Cell lysates (500 mg) were pre-cleared with 30 mL of protein A/
G plus-agarose beads (Santa Cruz) and 1.0 mg of normal rabbit
IgG for 1 hour at 4uC to remove nonspecific binding proteins
[63]. The pre-cleared cell lysates were incubated with 2.0 mg of
rabbit anti-vanin-1 antibody (Pierce) for 1 hour at 4uC, and then
with 30 mL of protein A/G plus agarose beads overnight at 4uC.
The beads were collected by centrifugation at 80006g for 30 s,
and washed four times with lysis buffer. The vanin-1 protein
complex was eluted by incubation with 30 mL of SDS loading
buffer in the presence of 100 mM DTT. The immunopurified
eluents were separated in 8% SDS-PAGE gel, and Western blot
analysis was performed.
Supporting Information
Figure S1 Descriptive characteristics of SBP (A), DBP (B), age
(C) and BMI (D) for the 19 COGENT consortium cohorts. The
mean and SD are presented for each cohort.
(PDF)
Figure S2 Antihypertensive medication rates for the 19
COGENT consortium cohorts.
(PDF)
Figure S3 Homology model for vanin-1 protein. The vanin-1
three-dimensional atomic model was built using I-TASSER server
(http://zhanglab.ccmb.med.umich.edu/I-TASSER) [48]. The
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predicted b-sheet regions are in red; a-helix, cyan; loop, purple.
The putative catalytic triad residues (E78, K178 and C211) are
shown as a sphere model. T26 and N131 are shown as a stick
model.
(PDF)
Table S1 The allele frequency of rs2272996 in the different
studies of the COGENT consortium.
(DOCX)
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